About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker ALKS · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Oct 29, 2026A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants Wi…
NCT07755410 · Attention Deficit Disorder With Hyperactivity (ADHD)
ALKS 7290, Placebo
ALKS
Alkermes, Inc.
Phase 2Recruiting312Jul 2027Registry ↗
Oct 28, 2026A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressant…
NCT07901179 · Major Depressive Disorder (MDD)
ALKS 7290 Dose, Placebo
ALKS
Alkermes, Inc.
Phase 2Recruiting180Jan 2028Registry ↗
Oct 9, 2026A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
NCT06767683 · Narcolepsy Type 1, Narcolepsy Type 2
ALKS 2680, 4mg, ALKS 2680, 6mg
ALKS
Alkermes, Inc.
Phase 2/3Recruiting786Jun 2030Registry ↗
Oct 7, 2026A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Ty…
NCT07540897 · Narcolepsy Type 1
ALKS 2680 Dose 1, ALKS 2680 Dose 2
ALKS
Alkermes, Inc.
Phase 3Recruiting150Jun 2027Registry ↗
Oct 7, 2026A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
NCT07502443 · Narcolepsy Type 2
ALKS 2680 Dose 1, ALKS 2680 Dose 2
ALKS
Alkermes, Inc.
Phase 3Recruiting176May 2027Registry ↗
Oct 7, 2026A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
NCT07455383 · Narcolepsy Type 1
ALKS 2680 Dose 1, ALKS 2680 Dose 2
ALKS
Alkermes, Inc.
Phase 3Recruiting150May 2027Registry ↗
Sep 25, 2026A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomn…
NCT06843590 · Idiopathic Hypersomnia
ALKS 2680, Placebo
ALKS
Alkermes, Inc.
Phase 2Active, not recruiting126Nov 2026Registry ↗
Aug 14, 2026Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schiz…
NCT05303064 · Schizophrenia, Bipolar I Disorder
OLZ/SAM, Olanzapine
ALKS
Alkermes, Inc.
Phase 3Recruiting220Sep 2026Registry ↗
Aug 14, 2026Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
NCT04987229 · Bipolar I Disorder, Schizophrenia
OLZ/SAM
ALKS
Alkermes, Inc.
Phase 3Enrolling by invitation236Sep 2027Registry ↗
Aug 4, 2026An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipola…
NCT07744113 · Bipolar 1 Disorder, Schizophrenia Disorder
OLZ/SAM
ALKS
Alkermes, Inc.
—Available——Registry ↗
Jun 10, 2026A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (A…
NCT06358950 · Narcolepsy Type 1
ALKS 2680, Placebo
ALKS
Alkermes, Inc.
Phase 2Completed92Jun 19, 2025Registry ↗
Feb 27, 2026A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
NCT06555783 · Narcolepsy Type 2
ALKS 2680, Placebo
ALKS
Alkermes, Inc.
Phase 2Completed93Nov 11, 2025Registry ↗
Sep 26, 2024Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38…
NCT03201757 · Schizophrenia, Schizophreniform Disorder
ALKS 3831
ALKS
Alkermes, Inc.
Phase 3Completed523Sep 6, 2023Registry ↗
Nov 22, 2023Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder
NCT04987658 · Bipolar I Disorder
OLZ/SAM
ALKS
Alkermes, Inc.
Phase 1Completed7Aug 11, 2023Registry ↗
Feb 10, 2023Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan
NCT05547100 · Focus of Study is on Healthy Lactating Women
LYBALVI
ALKS
Alkermes, Inc.
Phase 1Completed12Nov 19, 2022Registry ↗
Feb 2, 2023Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)
NCT03919994 · Schizophrenia
ALKS
Alkermes, Inc.
—Completed338Jan 4, 2023Registry ↗
Jan 19, 2023Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently D…
NCT03187769 · Schizophrenia, Schizophreniform Disorders
ALKS 3831, Olanzapine
ALKS
Alkermes, Inc.
Phase 3Completed426Dec 1, 2021Registry ↗
Sep 2, 2022Phase 1 ALKS 1140 in Healthy Adults
NCT05019105 · Central Nervous System Diseases
Placebo, ALKS 1140
ALKS
Alkermes, Inc.
Phase 1Terminated20Aug 23, 2022Registry ↗
Oct 8, 2021A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
NCT02161718 · Schizophrenia, Alcohol Use Disorder
Samidorphan + olanzapine (ALKS 3831), Placebo + olanzapine
ALKS
Alkermes, Inc.
Phase 2Completed300Jan 11, 2017Registry ↗
Oct 6, 2021A Study of ALKS 3831 in Adults With Schizophrenia
NCT01903837 · Schizophrenia
Samidorphan (Low Dose), Samidorphan (Medium Dose)
ALKS
Alkermes, Inc.
Phase 2Completed347Dec 2014Registry ↗
Jul 21, 2021A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
NCT02873208 · Schizophrenia
ALKS 3831
ALKS
Alkermes, Inc.
Phase 3Completed266Oct 17, 2019Registry ↗
Jul 16, 2021A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)
NCT03610048 · Refractory Major Depressive Disorder
ALKS 5461
ALKS
Alkermes, Inc.
Phase 3Terminated175May 1, 2020Registry ↗
Apr 8, 2021A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)
NCT03188185 · Major Depressive Disorder
ALKS 5461, ALKS 5461 Placebo
ALKS
Alkermes, Inc.
Phase 3Completed278Feb 26, 2020Registry ↗
Aug 11, 2020A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
NCT03345979 · Schizophrenia
Aripiprazole Lauroxil, Paliperidone Palmitate
ALKS
Alkermes, Inc.
Phase 3Completed200Mar 12, 2019Registry ↗
Feb 20, 2020A 28 Day Parallel Group Study to Assess the Effects of RDN-929
NCT03963973 · Healthy
RDN-929 oral capsule, Placebo oral capsule
ALKS
Alkermes, Inc.
Phase 1Terminated7Jan 22, 2020Registry ↗
Feb 20, 2020Single and Multiple Ascending Dose and Food Effect PK Study in Healthy Adult and Elderly Subjects
NCT03668314 · Healthy
RDN-929, Placebo oral capsule
ALKS
Alkermes, Inc.
Phase 1Completed84Apr 15, 2019Registry ↗
Feb 20, 2020A Non-therapeutic Feasibility Study of the Radioligand [11C]-UCB-J for Imaging Synaptic Density
NCT03577262 · Healthy, Alzheimer Disease
[11C]-UCB-J
ALKS
Alkermes, Inc.
Early phase 1Completed19Aug 2, 2019Registry ↗
Feb 10, 2020A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
NCT02694328 · Schizophrenia
ALKS 3831, Olanzapine
ALKS
Alkermes, Inc.
Phase 3Completed561Nov 7, 2018Registry ↗
Aug 14, 2019A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study
NCT02218008 · Major Depressive Disorder
ALKS 5461, Placebo
ALKS
Alkermes, Inc.
Phase 3Completed407Sep 2016Registry ↗
Aug 14, 2019A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study
NCT02158533 · Major Depressive Disorder
High Dose ALKS 5461, Low Dose ALKS 5461
ALKS
Alkermes, Inc.
Phase 3Completed385Dec 2015Registry ↗
Aug 14, 2019A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
NCT02085135 · Major Depressive Disorder
ALKS 5461
ALKS
Alkermes, Inc.
Phase 3Completed66Sep 2014Registry ↗
Jul 26, 2019A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
NCT02669758 · Schizophrenia
ALKS 3831
ALKS
Alkermes, Inc.
Phase 3Completed281Jun 29, 2018Registry ↗
Jun 25, 2019A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
NCT02158546 · Major Depressive Disorder
ALKS 5461, Placebo
ALKS
Alkermes, Inc.
Phase 3Completed447Dec 2015Registry ↗
May 21, 2019A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
NCT01500200 · Major Depressive Disorder
ALKS 5461, Placebo
ALKS
Alkermes, Inc.
Phase 2Completed142Mar 2013Registry ↗
Mar 6, 2019Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to Fi…
NCT02537574 · Opioid Use Disorder
NTX/BUP, NTX/PBO-B
ALKS
Alkermes, Inc.
Phase 3Completed380Oct 27, 2016Registry ↗
Feb 12, 2019Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder…
NCT02696434 · Opioid Use Disorder
Naltrexone, Placebo
ALKS
Alkermes, Inc.
Phase 3Completed101Nov 2017Registry ↗
Jan 30, 2019A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS…
NCT01469039 · Schizophrenia
ALKS 9072, Placebo
ALKS
Alkermes, Inc.
Phase 3Completed623Jan 2014Registry ↗
Dec 14, 2018A Long-Term Safety Study of ALKS 5461
NCT02141399 · Major Depressive Disorder
ALKS 5461
ALKS
Alkermes, Inc.
Phase 3Completed1,485Nov 20, 2017Registry ↗
Dec 11, 2018ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professio…
NCT00834080 · Opiate Dependence
Medisorb naltrexone 380 mg
ALKS
Alkermes, Inc.
Phase 3Completed38May 2012Registry ↗
Dec 4, 2018A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia
NCT02634320 · Schizophrenia
Aripiprazole Lauroxil
ALKS
Alkermes, Inc.
Phase 4Completed51Jul 11, 2017Registry ↗
Nov 16, 2018ALK21-025: Vivitrol's Cost and Treatment Outcomes Registry
NCT01422837 · Opioid Dependence
ALKS
Alkermes, Inc.
—Completed403Oct 2013Registry ↗
Sep 25, 2018A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
NCT01626456 · Schizophrenia
ALKS 9072, Low, ALKS 9072, High
ALKS
Alkermes, Inc.
Phase 3Completed478Apr 2015Registry ↗
Aug 29, 2018An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
NCT02320032 · Schizophrenia
Aripiprazole Lauroxil
ALKS
Alkermes, Inc.
Phase 1Completed140Apr 2016Registry ↗
Aug 29, 2018A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia
NCT01493726 · Schizophrenia
ALKS 9072, Low dose, ALKS 9072, Med dose
ALKS
Alkermes, Inc.
Phase 1Completed88Jun 2013Registry ↗
Jun 27, 2018A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)
NCT02634346 · Schizophrenia
ALK3831, Olanzapine
ALKS
Alkermes, Inc.
Phase 3Completed403May 25, 2017Registry ↗
Aug 25, 2017An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
NCT01895452 · Schizophrenia
ALKS 9072, Low Dose, ALKS 9072, High Dose
ALKS
Alkermes, Inc.
Phase 3Completed291Jun 2016Registry ↗
Aug 22, 2017An Insulin Sensitivity Study in Healthy Subjects
NCT02922426 · Healthy Volunteers
ALKS 3831, Olanzapine
ALKS
Alkermes, Inc.
Phase 1Completed60Jul 20, 2017Registry ↗
Jul 11, 2017ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults
NCT01218958 · Alcoholism
Medisorb naltrexone 190 mg, Medisorb naltrexone 380 mg
ALKS
Alkermes, Inc.
Phase 3Completed624Sep 2003Registry ↗
Jul 11, 2017ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alc…
NCT00511836 · Alcohol Dependence
VIVITROL 380 mg, Placebo
ALKS
Alkermes, Inc.
Phase 4Completed31Jun 2009Registry ↗
Jul 11, 2017ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults
NCT00156923 · Alcoholism
Medisorb naltrexone 380 mg, Medisorb naltrexone 190 mg
ALKS
Alkermes, Inc.
Phase 3Completed108Jan 2007Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:04 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances